ArticleInternational journal of molecular sciences2023
Superiority of [
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Comparison of PERCIST5, imPERCIST5, and PERCIMT Criteria for Early Assessment of Pembrolizumab Response with FDG-PET/CT in Metastatic Bladder Cancer Patients.Pharmaceuticals (Basel, Switzerland) · 2025Article
- From chronic obstructive pulmonary disease (COPD) to lung cancer: a Mendelian randomization study revealing mediation pathways through plasma metabolomics, proteomics, and immunophenotyping.Discover oncology · 2025Article
- Nuclear Medicine and Molecular Imaging in Urothelial Cancer: Current Status and Future Directions.Cancers · 2025Review
- PET Imaging in Bladder Cancer: An Update and Future Direction.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Asymmetric and symmetric protein arginine methylation in methionine-addicted human cancer cells.PloS one · 2023Article
- Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse Model.In vivo (Athens, Greece)Article
- Induction of the DNA-Repair Gene POLQ only in BRCA1-mutant Breast-Cancer Cells by Methionine Restriction.Cancer genomics & proteomicsArticle
- The Combination of Methionine Restriction and Docetaxel Synergistically Arrests Androgen-independent Prostate Cancer But Not Normal Cells.Cancer diagnosis & prognosisArticle
- Synergy of Rapamycin and Methioninase on Colorectal Cancer Cells Requires Simultaneous and Not Sequential Administration: Implications for mTOR Inhibition.Cancer diagnosis & prognosisArticle
- Synergistic Eradication of Fibrosarcoma With Acquired Ifosfamide Resistance Using Methionine Restriction Combined With Ifosfamide in Nude-mouse Models.In vivo (Athens, Greece)Article
- Oncogenes and Methionine Addiction of Cancer: Role ofCancer genomics & proteomicsArticle
- Methionine Restriction Must Be Continuously Maintained to Selectively Inhibit Cancer Cells Co-cultured With Normal Cells.Cancer diagnosis & prognosisArticle
- Synergy of Combining Methionine Restriction and Chemotherapy: The Disruptive Next Generation of Cancer Treatment.Cancer diagnosis & prognosisReview
- Methionine Restriction Increases Exosome Production and Secretion in Breast Cancer Cells.Cancer genomics & proteomicsArticle
- [In vivo (Athens, Greece)Article
- Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Positron emission tomography (PET) is widely used to detect cancers. The usual isotope for PET imaging of cancer is [
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.